RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN GILEAD SCIENCES, INC. AND HOOKIPA BIOTECH AGResearch Collaboration and License Agreement • January 17th, 2019 • HOOKIPA Pharma Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 17th, 2019 Company Industry JurisdictionThis RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is made as of June 4, 2018 (the “Effective Date”), by and between Gilead Sciences, Inc., a Delaware corporation having an office at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”) and Hookipa Biotech AG, an Austrian corporation (Aktiengesellschaft) having an office at St Marx Vienna Bio Center: Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria (“Hookipa”). Gilead and Hookipa are each referred to individually as a “Party” and together as the “Parties.”
ContractExclusive License Agreement • January 17th, 2019 • HOOKIPA Pharma Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 17th, 2019 Company IndustryCONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
ContractExclusive License Agreement • January 17th, 2019 • HOOKIPA Pharma Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 17th, 2019 Company IndustryCONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
ContractLicense Agreement • January 17th, 2019 • HOOKIPA Pharma Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 17th, 2019 Company IndustryCONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THE NATIONAL INSTITUTES OF HEALTH BIOLOGICAL MATERIALS LICENSE AGREEMENTLicense Agreement • January 17th, 2019 • HOOKIPA Pharma Inc. • Pharmaceutical preparations • District of Columbia
Contract Type FiledJanuary 17th, 2019 Company Industry JurisdictionThis Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A. and Hookipa Biotech AG (“Licensee”), a corporation of Vienna, Austria, having an office at Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria.